{"id":36554,"date":"2017-03-14T17:00:29","date_gmt":"2017-03-14T16:00:29","guid":{"rendered":"https:\/\/www.syncrosome.com\/?p=47"},"modified":"2026-04-17T17:51:08","modified_gmt":"2026-04-17T15:51:08","slug":"understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model","status":"publish","type":"post","link":"https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/","title":{"rendered":"Understanding Dyskinesia in 6 OHDA rats Parkinson preclinical model"},"content":{"rendered":"<p>The pathophysiological mechanisms leading to Dyskinesia in Parkinson\u2019s preclinical models (PD) after long-term treatment with levodopa remain unclear. <!--more-->This study investigates the neuronal firing characteristics of the entopeduncular nucleus (EPN), the rat equivalent of the human globus pallidus internus and output nucleus of the basal ganglia, and its coherence with the motor cortex (MCx) field potentials in the unilateral 6-OHDA rat model of PD with and without levodopa-induced dyskinesias (LID). 6-hydroxydopamine-lesioned hemiparkinsonian (HP) rats, 6-OHDA-lesioned HP rats with LID (HP-LID) rats, and na\u00efve controls were used for recording of single-unit activity under urethane (1.4 g\/kg, i.p) anesthesia in the EPN \u00abon\u00bb and \u00aboff\u00bb levodopa. Over the MCx, the electrocorticogram output was recorded. Analysis of single-unit activity in the EPN showed enhanced firing rates, burst activity, and irregularity compared to na\u00efve controls, which did not differ between drug-na\u00efve HP and HP-LID rats. Analysis of EPN spike coherence and phase-locked ratio with MCx field potentials showed a shift of low (12\u201319 Hz) and high (19\u201330 Hz) beta oscillatory activity between HP and HP-LID groups. EPN theta phase-locked ratio was only enhanced in HP-LID compared to HP rats. Overall, levodopa injection had no stronger effect in HP-LID rats than in HP rats. Altered coherence and changes in the phase lock ratio of spike and local field potentials in the beta range may play a role for the development of LID.<\/p>\n<p>from Neurology via xlomafota13 on Inoreader http:\/\/ift.tt\/1Rhor71<br \/>\nvia IFTTT<\/p>\n<p>About Syncrosome:<br \/>\nSyncrosome is a scientific preclinical CRO based in France focused on validating animal disease models to assess the efficacy of new compounds in the field of CNS, Cardiovascular, Gastrointestinal and Respiratory diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Discover Understanding Dyskinesia in 6 OHDA rats Parkinson preclinical model: The pathophysiological mechanisms leading to Dyskinesia in Parkinson\u2019s preclinical models (PD) after\u2026<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[207],"tags":[],"aire-therapeutique":[229],"class_list":["post-36554","post","type-post","status-publish","format-standard","hentry","category-science-and-innovation","aire-therapeutique-neurologie-cns"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Understanding Dyskinesia in 6 OHDA rats Parkinson preclinical model - ETAP-LAB<\/title>\n<meta name=\"description\" content=\"Syncrosome preclinical Central Nervous System CRO, 6-OHDA, Akinesia, L-DOPA, Dyskinesia Parkinson preclinical model, neuroprotection, anti-inflammatory\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Understanding Dyskinesia in 6 OHDA rats Parkinson preclinical model - ETAP-LAB\" \/>\n<meta property=\"og:description\" content=\"Syncrosome preclinical Central Nervous System CRO, 6-OHDA, Akinesia, L-DOPA, Dyskinesia Parkinson preclinical model, neuroprotection, anti-inflammatory\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/\" \/>\n<meta property=\"og:site_name\" content=\"ETAP-LAB\" \/>\n<meta property=\"article:published_time\" content=\"2017-03-14T16:00:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-17T15:51:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/04\/OpenGraph-defaut-Etap-Lab-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1800\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ana\u00efs GAVOILLE\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ana\u00efs GAVOILLE\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/science-and-innovation\\\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/science-and-innovation\\\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\\\/\"},\"author\":{\"name\":\"Ana\u00efs GAVOILLE\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/person\\\/5795847a84eb95e1faecaac7eaf85ba9\"},\"headline\":\"Understanding Dyskinesia in 6 OHDA rats Parkinson preclinical model\",\"datePublished\":\"2017-03-14T16:00:29+00:00\",\"dateModified\":\"2026-04-17T15:51:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/science-and-innovation\\\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\\\/\"},\"wordCount\":284,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#organization\"},\"articleSection\":[\"Science and innovation\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/science-and-innovation\\\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/science-and-innovation\\\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\\\/\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/science-and-innovation\\\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\\\/\",\"name\":\"Understanding Dyskinesia in 6 OHDA rats Parkinson preclinical model - ETAP-LAB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#website\"},\"datePublished\":\"2017-03-14T16:00:29+00:00\",\"dateModified\":\"2026-04-17T15:51:08+00:00\",\"description\":\"Syncrosome preclinical Central Nervous System CRO, 6-OHDA, Akinesia, L-DOPA, Dyskinesia Parkinson preclinical model, neuroprotection, anti-inflammatory\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/science-and-innovation\\\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/science-and-innovation\\\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/science-and-innovation\\\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Science and innovation\",\"item\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/science-and-innovation\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Understanding Dyskinesia in 6 OHDA rats Parkinson preclinical model\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\",\"name\":\"Etap Lab\",\"description\":\"CRO Services\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#organization\",\"name\":\"Etap Lab\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png\",\"contentUrl\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png\",\"width\":550,\"height\":550,\"caption\":\"Etap Lab\"},\"image\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/etap-lab\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/person\\\/5795847a84eb95e1faecaac7eaf85ba9\",\"name\":\"Ana\u00efs GAVOILLE\",\"description\":\"Marketing expert at ETAP-LAB.\",\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/anais-gavoille-54lorraine\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Understanding Dyskinesia in 6 OHDA rats Parkinson preclinical model - ETAP-LAB","description":"Syncrosome preclinical Central Nervous System CRO, 6-OHDA, Akinesia, L-DOPA, Dyskinesia Parkinson preclinical model, neuroprotection, anti-inflammatory","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/","og_locale":"en_US","og_type":"article","og_title":"Understanding Dyskinesia in 6 OHDA rats Parkinson preclinical model - ETAP-LAB","og_description":"Syncrosome preclinical Central Nervous System CRO, 6-OHDA, Akinesia, L-DOPA, Dyskinesia Parkinson preclinical model, neuroprotection, anti-inflammatory","og_url":"https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/","og_site_name":"ETAP-LAB","article_published_time":"2017-03-14T16:00:29+00:00","article_modified_time":"2026-04-17T15:51:08+00:00","og_image":[{"width":1800,"height":1200,"url":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/04\/OpenGraph-defaut-Etap-Lab-3.jpg","type":"image\/jpeg"}],"author":"Ana\u00efs GAVOILLE","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ana\u00efs GAVOILLE","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/#article","isPartOf":{"@id":"https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/"},"author":{"name":"Ana\u00efs GAVOILLE","@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/person\/5795847a84eb95e1faecaac7eaf85ba9"},"headline":"Understanding Dyskinesia in 6 OHDA rats Parkinson preclinical model","datePublished":"2017-03-14T16:00:29+00:00","dateModified":"2026-04-17T15:51:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/"},"wordCount":284,"commentCount":0,"publisher":{"@id":"https:\/\/www.etap-lab.com\/en\/#organization"},"articleSection":["Science and innovation"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/","url":"https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/","name":"Understanding Dyskinesia in 6 OHDA rats Parkinson preclinical model - ETAP-LAB","isPartOf":{"@id":"https:\/\/www.etap-lab.com\/en\/#website"},"datePublished":"2017-03-14T16:00:29+00:00","dateModified":"2026-04-17T15:51:08+00:00","description":"Syncrosome preclinical Central Nervous System CRO, 6-OHDA, Akinesia, L-DOPA, Dyskinesia Parkinson preclinical model, neuroprotection, anti-inflammatory","breadcrumb":{"@id":"https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.etap-lab.com\/en\/science-and-innovation\/understanding-dyskinesia-in-6-ohda-rats-parkinson-preclinical-model\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.etap-lab.com\/en\/"},{"@type":"ListItem","position":2,"name":"Science and innovation","item":"https:\/\/www.etap-lab.com\/en\/science-and-innovation\/"},{"@type":"ListItem","position":3,"name":"Understanding Dyskinesia in 6 OHDA rats Parkinson preclinical model"}]},{"@type":"WebSite","@id":"https:\/\/www.etap-lab.com\/en\/#website","url":"https:\/\/www.etap-lab.com\/en\/","name":"Etap Lab","description":"CRO Services","publisher":{"@id":"https:\/\/www.etap-lab.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.etap-lab.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.etap-lab.com\/en\/#organization","name":"Etap Lab","url":"https:\/\/www.etap-lab.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/03\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png","contentUrl":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/03\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png","width":550,"height":550,"caption":"Etap Lab"},"image":{"@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/etap-lab\/"]},{"@type":"Person","@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/person\/5795847a84eb95e1faecaac7eaf85ba9","name":"Ana\u00efs GAVOILLE","description":"Marketing expert at ETAP-LAB.","sameAs":["https:\/\/www.linkedin.com\/in\/anais-gavoille-54lorraine\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/posts\/36554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/comments?post=36554"}],"version-history":[{"count":0,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/posts\/36554\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/media?parent=36554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/categories?post=36554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/tags?post=36554"},{"taxonomy":"aire-therapeutique","embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/aire-therapeutique?post=36554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}